<h4>Objective</h4>The efficacy of regorafenib or fruquintinib in combination with PD-1/PD-L1 inhibitors for metastatic colorectal cancer (mCRC) treatment has not been elucidated. Here, CD274 is linked to metastatic colorectal cancer.